8,373 Biogen Inc. $BIIB Shares Purchased by Investors Asset Management of Georgia Inc. GA ADV

Investors Asset Management of Georgia Inc. GA ADV increased its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 811.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 9,405 shares of the biotechnology company’s stock after purchasing an additional 8,373 shares during the quarter. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Biogen were worth $2,124,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Biogen in the second quarter valued at $3,453,878,000. Primecap Management Co. CA purchased a new position in shares of Biogen during the second quarter worth about $3,274,304,000. Legal & General Group Plc acquired a new stake in shares of Biogen during the second quarter worth about $322,640,000. Bank of America Corp DE acquired a new stake in shares of Biogen during the second quarter worth about $241,172,000. Finally, Deutsche Bank AG acquired a new stake in shares of Biogen during the second quarter worth about $193,165,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen will present 76-week EMPAVELI data at ASN Kidney Week showing sustained proteinuria reduction, stabilized kidney function, and a consistent long-term safety profile in C3G and primary IC-MPGN patients. The results reinforce confidence in EMPAVELI following its expanded FDA indication and could support broader commercial adoption. Biogen ASN Kidney Week announcement
• Positive Sentiment: Investors are also focusing on Biogen’s expanding nephrology strategy, including investigational felzartamab programs in antibody-mediated rejection, IgA nephropathy, and primary membranous nephropathy. Phase 3 data from the TRANSCEND study is expected in the first half of 2027, offering a potential longer-term pipeline catalyst.
• Positive Sentiment: Wells Fargo raised its Biogen price target from $250 to $310 and maintained an “overweight” rating, signaling increased confidence in the company’s earnings and pipeline outlook.
• Neutral Sentiment: Biogen is scheduled to report third-quarter 2026 results on October 28. The approaching earnings event may be increasing investor interest, although management’s outlook and commercial performance will determine whether the recent momentum continues.
• Neutral Sentiment: Institutional positioning was mixed: 523 investors added BIIB shares in the latest quarter, while 379 reduced positions. Several large funds made substantial purchases, but other institutions reported significant selling.
• Negative Sentiment: EMPAVELI carries a boxed warning for potentially fatal infections and requires a restricted REMS program, risks that could limit prescribing and complicate market uptake. Felzartamab also remains unapproved and dependent on successful clinical trials.
• Negative Sentiment: Recent insider activity included two sales and no purchases by insiders over the past six months. In addition, the reported median analyst price target of $223.50 is below the current trading level, suggesting some valuation caution despite the new Wells Fargo target.

Biogen Stock Performance

BIIB traded up $10.40 on Tuesday, hitting $243.88. 725,838 shares of the company traded hands, compared to its average volume of 1,203,806. Biogen Inc. has a 12-month low of $138.00 and a 12-month high of $244.65. The company has a 50 day moving average of $220.49 and a 200-day moving average of $204.32. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $36.03 billion, a PE ratio of 43.19, a PEG ratio of 2.58 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company’s revenue was up 3.4% on a year-over-year basis. During the same period last year, the business posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Sell-side analysts anticipate that Biogen Inc. will post 12.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on BIIB shares. Wells Fargo & Company upped their target price on Biogen from $250.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday. Bank of America lowered their target price on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 21st. Guggenheim lifted their target price on shares of Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Seaport Research Partners upgraded shares of Biogen to an “outperform” rating in a research report on Monday, October 12th. Finally, HC Wainwright increased their price target on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $239.96.

Biogen Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.